Skip to content

When Are Immunosuppressants Prescribed for Sjögren's?

Published: | Updated:

Doctors prescribe immunosuppressants like methotrexate for Sjögren's syndrome when the disease causes systemic complications, such as inflammatory arthritis, lung disease, or neuropathy. These medications do not improve dry eyes or dry mouth, but instead protect organs from autoimmune damage.

Key Takeaways

  • Immunosuppressants like methotrexate are not prescribed to treat dry eyes or dry mouth in Sjögren's syndrome.
  • Doctors escalate treatment to immunosuppressants when Sjögren's causes systemic issues like inflammatory arthritis, lung disease, or neuropathy.
  • Rheumatologists use the ESSDAI score to measure systemic disease activity and guide treatment decisions.
  • Patients starting a stronger immunosuppressant will typically continue taking Plaquenil as a foundational therapy.
  • Taking systemic immunosuppressants requires routine blood work to monitor organ function and increased vigilance for infections.

When managing Primary Sjögren’s Syndrome, it can be confusing to understand why some patients take mild medications while others are prescribed stronger immunosuppressants like Methotrexate, Azathioprine, or Mycophenolate Mofetil. The short answer is: these potent medications are not prescribed to treat dry eyes or dry mouth [1]. Instead, doctors prescribe them when Sjögren’s syndrome escalates beyond the moisture-producing glands and begins attacking other organs and systems in the body [1][2].

The Line Between “Sicca” and “Systemic”

Sjögren’s is typically characterized by sicca symptoms (dryness of the eyes, mouth, and other mucous membranes). There is no strong evidence from randomized trials that traditional immunosuppressants improve this glandular dysfunction, meaning they will not help you produce more natural tears or saliva [1].

However, in a subset of patients, Sjögren’s causes systemic or extraglandular manifestations—meaning the immune system targets areas outside the glands [1][3]. While not everyone with Sjögren’s will develop these severe complications, when these systemic issues do become organ-threatening, doctors escalate treatment from baseline therapies like Hydroxychloroquine (Plaquenil) to advanced systemic therapies [1][2].

When is Escalation Necessary?

If you notice new symptoms like persistent joint swelling, shortness of breath, or numbness in your extremities, tell your doctor. Your rheumatologist may recommend stepping up to a stronger immunosuppressant if you develop complications such as:

  • Inflammatory Arthritis: Severe joint pain and swelling that doesn’t respond to Plaquenil alone. Methotrexate is frequently the standard go-to medication for this specific issue [1].
  • Lung Disease: Conditions like interstitial lung disease (ILD), where inflammation causes scarring in the lungs. Drugs like Mycophenolate Mofetil or Azathioprine are often used to stabilize lung function [4][5].
  • Neurological Involvement: Nerve damage, such as peripheral neuropathy, which can cause pain, tingling, or numbness in the hands and feet [1][6].
  • Kidney Disease or Vasculitis: Inflammation of the kidneys or blood vessels that requires aggressive treatment to prevent permanent damage [1][7].

How Doctors Make the Decision

To decide if you need these stronger medications, your doctor may calculate your ESSDAI score (EULAR Sjögren’s Syndrome Disease Activity Index) [8]. This is a validated tool that measures disease activity across 12 different organ systems [9]. A high ESSDAI score indicates active systemic disease and helps guide the decision to start stronger therapies [3].

Interestingly, because there is a lack of large-scale clinical trials specifically testing these drugs for Sjögren’s, doctors often rely on treatment guidelines established for closely related autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) [1][10]. This means your prescription is technically considered “off-label” for Sjögren’s, but this practice is very normal, well-researched, and standard in rheumatology [1].

Safety and Monitoring

These are potent medications that work by dampening down your entire immune system. Because of this, escalation comes with important safety trade-offs and responsibilities [11]. If you start these therapies, you will need:

  • Routine Lab Work: Regular blood tests are mandatory to monitor your liver, kidneys, and bone marrow function [11][12].
  • Infection Vigilance: You will be at a higher risk for infections. You should talk to your doctor about updating your vaccines before starting the medication and seek medical care promptly if you develop a fever.

What Happens to My Current Medications?

If your doctor prescribes Methotrexate, Azathioprine, or Mycophenolate Mofetil, you will likely continue your current regimen for dryness (like prescription eye drops or saliva stimulants). Additionally, Hydroxychloroquine (Plaquenil) is frequently continued as a foundational background therapy even after stronger drugs are added, as it helps manage overall disease activity [13][14].

Frequently Asked Questions

Do immunosuppressants help with dry eyes and dry mouth from Sjögren's?
No, medications like methotrexate and azathioprine are not prescribed to treat dryness. They are used when the immune system begins attacking other organs and systems, such as the joints, nerves, or lungs.
What symptoms mean my Sjögren's is becoming systemic?
Symptoms like persistent joint swelling, shortness of breath, or numbness in your hands and feet suggest the disease may be affecting areas outside your moisture glands. You should report these changes to your rheumatologist promptly.
What is the ESSDAI score used for in Sjögren's syndrome?
The ESSDAI score measures disease activity across 12 different organ systems. Rheumatologists use it to determine if your systemic disease is active enough to require stronger immunosuppressant therapies.
Do I stop taking Plaquenil if I start methotrexate for Sjögren's?
Typically, no. Hydroxychloroquine (Plaquenil) is often continued as a foundational therapy to manage overall disease activity, even after stronger immunosuppressants are added to your treatment plan.
What monitoring is required when taking immunosuppressants for Sjögren's?
Because these medications dampen your immune system, you will need routine blood tests to monitor your liver, kidneys, and bone marrow function. You will also be at a higher risk for infections and may need to update your vaccines.

Questions for Your Doctor

  • What is my current ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) score, and which specific areas are contributing to my systemic activity?
  • Are there specific markers in my bloodwork or imaging (like a lung CT or nerve conduction study) that indicate my disease is affecting organs beyond my tear and salivary glands?
  • If we add an immunosuppressant, will I continue taking Plaquenil as a foundational therapy?
  • How frequently will I need blood tests to monitor my liver and blood counts while on this new immunosuppressant?
  • Do I need to update any of my vaccines before starting this medication?

Questions for You

  • What symptoms first brought me to the doctor, and have they shifted from isolated dryness to include issues like joint pain, breathing difficulty, or nerve tingling?
  • Have I noticed any changes in my ability to perform daily tasks due to joint swelling or shortness of breath?
  • Am I prepared for the monitoring required, such as scheduling regular blood draws, if I escalate to a stronger immunosuppressant?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Primary Sjögren's Syndrome.

    Mariette X, Criswell LA

    The New England journal of medicine 2018; (378(10)):931-939 doi:10.1056/NEJMcp1702514.

    PMID: 29514034
  2. 2

    Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How.

    van Beers JJBC, Damoiseaux JGMC

    Biomolecules 2021; (11(1)) doi:10.3390/biom11010116.

    PMID: 33467204
  3. 3

    Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy.

    Parisis D, Chivasso C, Perret J, et al.

    Journal of clinical medicine 2020; (9(7)) doi:10.3390/jcm9072299.

    PMID: 32698400
  4. 4

    Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease.

    Erbasan F, Öğüt TS, Dilbil M, et al.

    Medicina clinica 2024; (163(10)):490-495 doi:10.1016/j.medcli.2024.06.012.

    PMID: 39174415
  5. 5

    Immune-mediated lung diseases: A narrative review.

    Sweis JJG, Sweis NWG, Alnaimat F, et al.

    Frontiers in medicine 2023; (10()):1160755 doi:10.3389/fmed.2023.1160755.

    PMID: 37089604
  6. 6

    Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review.

    Depascale R, Del Frate G, Gasparotto M, et al.

    Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211040696 doi:10.1177/1759720X211040696.

    PMID: 34616495
  7. 7

    Sjögren's Syndrome Associated with Fanconi's Syndrome and Osteomalacia.

    Gutierrez JO, Zurita MF, Zurita LA

    The American journal of case reports 2018; (19()):392-396 doi:10.12659/ajcr.907503.

    PMID: 29610453
  8. 8

    Association between memory B-cells and clinical and immunological features of primary Sjögren's syndrome and Sicca patients.

    Barcelos F, Martins C, Papoila A, et al.

    Rheumatology international 2018; (38(6)):1063-1073 doi:10.1007/s00296-018-4018-0.

    PMID: 29623391
  9. 9

    Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'.

    Wang B, Chen S, Xuan J, et al.

    Annals of the rheumatic diseases 2023; (82(3)):e67 doi:10.1136/annrheumdis-2020-219666.

    PMID: 33504477
  10. 10

    Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment.

    Both T, Dalm VA, van Hagen PM, van Daele PL

    International journal of medical sciences 2017; (14(3)):191-200 doi:10.7150/ijms.17718.

    PMID: 28367079
  11. 11

    Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: a multicenter cross-sectional study.

    Zhang Y, Li M, Zhang L, et al.

    Clinical rheumatology 2020; (39(9)):2677-2688 doi:10.1007/s10067-020-04992-x.

    PMID: 32146615
  12. 12

    Neurological involvement in primary Sjögren's syndrome: a retrospective analysis of clinical, radiological, laboratory and therapeutic correlations.

    Elshony H, Muddassir R, Almuhanna R, et al.

    BMJ neurology open 2025; (7(2)):e001227 doi:10.1136/bmjno-2025-001227.

    PMID: 41368033
  13. 13

    Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.

    van der Heijden EHM, Blokland SLM, Hillen MR, et al.

    The Lancet. Rheumatology 2020; (2(5)):e260-e269 doi:10.1016/S2665-9913(20)30057-6.

    PMID: 38273473
  14. 14

    Bone Mineral Density in Sjögren Syndrome Patients with and Without Distal Renal Tubular Acidosis.

    Both T, Zillikens MC, Hoorn EJ, et al.

    Calcified tissue international 2016; (98(6)):573-9 doi:10.1007/s00223-016-0112-z.

    PMID: 26873478

This page provides educational information about systemic treatments for Sjögren's syndrome. Always consult your rheumatologist to discuss whether immunosuppressants are appropriate for your specific symptoms and disease activity.

Stay up to date

Get notified when new research about Primary Sjögren's Syndrome is published.

No spam. Unsubscribe anytime.